Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363487 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL18870816 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL207772 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL1230711 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL5697575 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805415 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL547089 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL4286246 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21423108 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL30694436 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1533317-A1 | Nucleosides for imaging and treatment applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1027365-B1 | ANTITUMOUR URIDINE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6753309-B2 | ADMINISTERING URIDINE COMPOUND | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-06-22 | — | — | US | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-6703374-B1 | ACTIVATED BY THYMIDYLATE SYNTHASE AND/OR THYMIDINE KINASE ENZYME; ANTITUMOR AGENTS; DIAGNOSIS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-09 | — | — | US | disclosed |
| US-20030095921-A1 | Nucleosides for imaging and treatment applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, SECRETARY OF HEALTH AND HUMAN SERVICES | 2003-05-22 | — | — | US | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030049201-A1 | Nucleosides for imaging and treatment applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, SECRETARY OF HEALTH AND HUMAN SERVICES | 2003-03-13 | — | — | US | disclosed |
| US-20020165199-A1 | Nucleosides for imaging and treatment applications | THE GOV. OF THE USA RESPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2002-11-07 | — | — | US | disclosed |
| US-20020119094-A1 | Nucleosides for imaging and treatment applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, SECRETARY OF HEALTH AND HUMAN SERVICES | 2002-08-29 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| US-20020034473-A1 | Nucleosides for imaging and treatment applications | US HEALTH (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020022001-A1 | Nucleosides for imaging and treatment applications | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, SECRETARY OF HEALTH AND HUMAN SERVICES | 2002-02-21 | — | — | US | disclosed |
| EP-1027365-A2 | ANTITUMOUR URIDINE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999023104-A2 | ANTITUMOUR URIDINE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030049201-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2119/4885MTOR 2175/4885ALDH1A1 856/4885 |
| US-20030095921-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2134/4885MTOR 1944/4885ALDH1A1 1217/4885 |
| US-20020022001-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2134/4885MTOR 1944/4885ALDH1A1 1217/4885 |
| US-20020034473-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2134/4885MTOR 1944/4885ALDH1A1 1217/4885 |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | LMNA 1019/4885MTOR 3027/4885ALDH1A1 1466/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | LMNA 694/4885MTOR 3588/4885ALDH1A1 2416/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | LMNA 821/4885MTOR 3796/4885ALDH1A1 1128/4885 |
| US-20020165199-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2134/4885MTOR 1944/4885ALDH1A1 1217/4885 |
| US-20020119094-A1 | Nucleosides for imaging and treatment applications | TYMP, TK1, TYMS | LMNA 2134/4885MTOR 1944/4885ALDH1A1 1217/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | LMNA 1076/4885MTOR 3184/4885ALDH1A1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.